VERACYTE, INC.
VCYTNasdaq
$59.13
↓ -0.2%Jul 17 close · end-of-day
Price
1Y↑ +134.9%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$4.8B
Enterprise Value
$4.5B
P/E
54.8
P/S
8.9
P/B
3.6
EV/EBITDA
45.9
PEG
—
FCF Yield
3.2%
Dividend Yield
—
Revenue (TTM)
$541.7M
Net Income (TTM)
$88.1M
Free Cash Flow (TTM)
$155.3M
Gross Margin
70.9%
Operating Margin
14.3%
Net Margin
16.3%
ROE
6.6%
ROIC
7.0%
Debt / Equity
—
Net Cash
$263.1M
Return 1Y
+144.1%
Company profile
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas. It is also developing Percepta Genome Atlas to help inform lung cancer treatment decisions.
- CEO
- Marc A. Stapley
- Sector
- Services
- Industry
- Healthcare
- Employees
- 790
- Headquarters
- California
- Website
- veracyte.com
Management & directors
- Chambers RebeccaChief Financial Officer
- Leite JohnChief Commercial Officer-CLIA
- Mcguire AnnieEVP, General Counsel
- Stapley MarcChief Executive Officer
- Febbo Phillip G.Chief Scientific & Med Officer
- Wygant JonathanVP, Chief Accounting Officer
- Haas Kevin RichardChief Dev and Tech Officer
Roles derived from SEC Form 4 filings.
Earnings
VCYT Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$139.1M↑ +21.5%
Diluted EPS$0.35↑ +288.9%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $117.5M | $219.5M | $296.5M | $361.1M | $445.8M | $517.1M |
| Gross profit | — | — | $175.7M | $229.7M | $298.1M | $362.5M |
| Operating income | -$35.4M | -$81.9M | -$41.1M | -$85.8M | $16.1M | $57.8M |
| Net income | -$34.9M | -$75.6M | -$36.6M | -$74.4M | $24.1M | $66.4M |
| Diluted EPS | -$0.66 | -$1.11 | -$0.51 | -$1.02 | $0.31 | $0.82 |
| Operating cash flow | -$9.7M | -$31.6M | $7.5M | $44.2M | $75.1M | $136.3M |
| Free cash flow | -$12.5M | -$37.0M | -$1.0M | $34.3M | $63.8M | $126.6M |
| Gross margin | — | — | 59.2% | 63.6% | 66.9% | 70.1% |
| Operating margin | -30.1% | -37.3% | -13.9% | -23.8% | 3.6% | 11.2% |
| Net margin | -29.7% | -34.4% | -12.3% | -20.6% | 5.4% | 12.8% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $114.4M | $115.9M | $118.6M | $114.5M | $130.2M | $131.9M | $140.6M | $139.1M |
| Gross profit | $77.9M | $79.0M | $78.8M | $79.5M | $89.8M | $91.3M | $102.0M | $101.2M |
| Operating income | $4.6M | $12.0M | $4.2M | $2.9M | -$5.3M | $22.9M | $37.2M | $22.6M |
| Net income | $5.7M | $15.2M | $5.1M | $7.0M | -$980,000.00 | $19.1M | $41.2M | $28.7M |
| Diluted EPS | $0.07 | $0.19 | $0.07 | $0.09 | -$0.01 | $0.24 | $0.50 | $0.35 |
| Operating cash flow | $29.6M | $30.0M | $24.5M | $5.4M | $33.6M | $44.8M | $52.6M | $35.2M |
| Free cash flow | $26.8M | $27.7M | $20.4M | $3.5M | $32.3M | $42.0M | $48.8M | $32.3M |
| Gross margin | 68.1% | 68.2% | 66.4% | 69.5% | 69.0% | 69.2% | 72.5% | 72.7% |
| Operating margin | 4.0% | 10.4% | 3.5% | 2.5% | -4.0% | 17.4% | 26.4% | 16.3% |
| Net margin | 5.0% | 13.1% | 4.3% | 6.2% | -0.8% | 14.5% | 29.3% | 20.6% |
Company news
Jul 17, 2026
Jul 9, 2026
Jul 8, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-18 | EASTHAM KARIN | Sale | 3,200 | $52.78 | $168,906.24 | filing |
| 2026-06-18 | EASTHAM KARIN | Sale | 529 | $53.55 | $28,328.16 | filing |
| 2026-06-11 | JONES EVAN/ FA | Award | 5,272 | $0.00 | $0.00 | filing |
| 2026-06-11 | Shafer David Brent | Award | 5,272 | $0.00 | $0.00 | filing |
| 2026-06-11 | Barr Eliav | Award | 5,272 | $0.00 | $0.00 | filing |
| 2026-06-11 | Holstein Jens | Award | 5,272 | $0.00 | $0.00 | filing |
| 2026-06-11 | Bhanji Muna | Award | 5,272 | $0.00 | $0.00 | filing |
| 2026-06-11 | Miller Thomas F. | Award | 5,272 | $0.00 | $0.00 | filing |
| 2026-06-11 | EPSTEIN ROBERT S | Award | 5,272 | $0.00 | $0.00 | filing |
| 2026-06-11 | EASTHAM KARIN | Award | 5,272 | $0.00 | $0.00 | filing |
| 2026-06-04 | Stapley Marc· Chief Executive Officer | Sale | 138,051 | $50.12 | $6.9M | filing |
| 2026-06-04 | Stapley Marc· Chief Executive Officer | Option exercise | 138,051 | $36.60 | $5.1M | filing |
| 2026-06-04 | Leite John· Global Chief Commercial Off | Sale | 13,975 | $50.07 | $699,732.44 | filing |
| 2026-06-04 | Chambers Rebecca· Chief Financial Officer | Sale | 1,961 | $50.09 | $98,229.04 | filing |
| 2026-06-04 | McGuire Annie· EVP, General Counsel | Sale | 1,776 | $50.12 | $89,007.44 | filing |
| 2026-06-04 | Chambers Rebecca· Chief Financial Officer | Sale | 1,600 | $49.28 | $78,853.76 | filing |
| 2026-06-04 | McGuire Annie· EVP, General Counsel | Sale | 1,400 | $49.31 | $69,028.54 | filing |
| 2026-06-02 | Stapley Marc· Chief Executive Officer | Tax withholding | 9,012 | $47.80 | $430,773.60 | filing |
| 2026-06-02 | Leite John· Global Chief Commercial Off | Tax withholding | 4,059 | $47.80 | $194,020.20 | filing |
| 2026-06-02 | Febbo Phillip G.· Chief Scientific & Med Officer | Tax withholding | 3,730 | $47.80 | $178,294.00 | filing |
| 2026-06-02 | Chambers Rebecca· Chief Financial Officer | Tax withholding | 3,693 | $47.80 | $176,525.40 | filing |
| 2026-06-02 | McGuire Annie· EVP, General Counsel | Tax withholding | 3,292 | $47.80 | $157,357.60 | filing |
| 2026-06-02 | Wygant Jonathan· VP, Chief Accounting Officer | Tax withholding | 1,361 | $47.80 | $65,055.80 | filing |
| 2026-05-22 | Wygant Jonathan· VP, Chief Accounting Officer | Sale | 24,000 | $45.40 | $1.1M | filing |
| 2026-05-22 | Wygant Jonathan· VP, Chief Accounting Officer | Option exercise | 24,000 | $24.80 | $595,200.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.